[Form 4] Helix Acquisition Corp. II Insider Trading Activity
John P. Schmid reported a corporate reorganization-driven conversion that resulted in direct ownership of 30,000 common shares of BridgeBio Oncology Therapeutics, Inc. (ticker BBOT). The Form 4 shows a transaction dated 08/11/2025 where 30,000 Helix Class B ordinary shares were recorded in connection with a business combination and domestication that converted Helix Class B to Helix Class A on a one-for-one basis and then Helix Class A to the Issuer's common stock one-for-one.
The filing states the reporting person was a director of Helix prior to the domestication and resigned effective 08/11/2025, immediately prior to the domestication. Following the reported conversion, the Form 4 lists 30,000 shares beneficially owned following the transaction, held directly.
John P. Schmid ha segnalato una conversione dovuta a una riorganizzazione societaria che ha comportato la titolarit脿 diretta di 30,000 azioni ordinarie di BridgeBio Oncology Therapeutics, Inc. (ticker BBOT). Il Form 4 riporta una transazione datata 08/11/2025 in cui sono state registrate 30,000 azioni ordinarie Classe B di Helix nell'ambito di una combinazione aziendale e di un trasferimento di domicilio societario che ha convertito le azioni Classe B di Helix in Classe A su base uno a uno e successivamente le azioni Classe A nelle azioni ordinarie dell'emittente, sempre uno a uno.
La comunicazione indica che la persona che ha presentato il rapporto era membro del consiglio di Helix prima della domesticazione e si 猫 dimessa con effetto 08/11/2025, immediatamente prima della domesticazione. A seguito della conversione segnalata, il Form 4 elenca 30,000 azioni possedute beneficiariamente dopo la transazione, detenute direttamente.
John P. Schmid inform贸 una conversi贸n derivada de una reorganizaci贸n corporativa que result贸 en la propiedad directa de 30,000 acciones ordinarias de BridgeBio Oncology Therapeutics, Inc. (s铆mbolo BBOT). El Form 4 muestra una transacci贸n con fecha 08/11/2025 en la que se registraron 30,000 acciones ordinarias Clase B de Helix en relaci贸n con una combinaci贸n de negocios y una domesticaci贸n que convirti贸 las Clase B de Helix en Clase A una a una y luego las Clase A en acciones ordinarias del emisor, tambi茅n una a una.
La presentaci贸n indica que la persona informante era directora de Helix antes de la domesticaci贸n y renunci贸 con efecto 08/11/2025, inmediatamente antes de la domesticaci贸n. Tras la conversi贸n reportada, el Form 4 lista 30,000 acciones de propiedad beneficiaria despu茅s de la transacci贸n, mantenidas directamente.
John P. Schmid鞚� 旮办梾 鞛幐鞙茧 鞚疙暅 鞝勴櫂鞙茧 BridgeBio Oncology Therapeutics, Inc.(韹办护 BBOT)鞚� 氤错喌欤� 30,000欤茧ゼ 歆侅为 氤挫湢頃橁矊 霅橃棃雼り碃 氤搓碃頄堨姷雼堧嫟. Form 4鞐愲姅 08/11/2025鞚检瀽 瓯半灅臧� 旮办灛霅橃柎 鞛堨溂氅�, 靷梾 瓴绊暕 氚� 氩曥澑 甑偞頇�(domestication)鞕� 甏�霠晿鞐� Helix 韥措灅鞀� B 氤错喌欤� 30,000欤缄皜 旮半霅橃棃瓿�, 鞚措摛鞚� 1雽�1搿� Helix 韥措灅鞀� A搿� 鞝勴櫂霅� 霋� 雼れ嫓 1雽�1搿� 氚滍枆須岇偓鞚� 氤错喌欤茧 鞝勴櫂霅� 瓴冹溂搿� 雮橅儉雮╇媹雼�.
靹滊鞐愲姅 氤搓碃鞚胳澊 domestication 鞚挫爠鞐� Helix鞚� 鞚挫偓鞓�鞙茧┌ domestication 歆侅爠鞐� 08/11/2025鞛愲 靷瀯頄堧嫟瓿� 鞝來榾 鞛堨姷雼堧嫟. 氤搓碃霅� 鞝勴櫂 鞚错泟 Form 4鞐愲姅 瓯半灅 頉� 靾橅槣鞝� 靻岇湢搿滌劀 30,000欤茧ゼ 歆侅为 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 霌膘灛霅橃柎 鞛堨姷雼堧嫟.
John P. Schmid a d茅clar茅 une conversion li茅e 脿 une r茅organisation d'entreprise ayant entra卯n茅 la propri茅t茅 directe de 30,000 actions ordinaires de BridgeBio Oncology Therapeutics, Inc. (symbole BBOT). Le Form 4 indique une op茅ration dat茅e du 08/11/2025 au cours de laquelle 30,000 actions ordinaires de classe B de Helix ont 茅t茅 enregistr茅es dans le cadre d'une fusion d'entreprise et d'une domestication qui a converti les actions Helix de classe B en classe A sur une base un pour un, puis les actions de classe A en actions ordinaires de l'茅metteur, 茅galement un pour un.
Le d茅p么t pr茅cise que la personne d茅clar茅e 茅tait administrateur chez Helix avant la domestication et a d茅missionn茅 avec effet au 08/11/2025, imm茅diatement avant la domestication. Suite 脿 la conversion signal茅e, le Form 4 indique 30,000 actions d茅tenues b茅n茅ficiairement apr猫s la transaction, d茅tenues directement.
John P. Schmid meldete eine durch eine Unternehmensumstrukturierung veranlasste Umwandlung, die zu unmittelbarem Eigentum an 30,000 Stammaktien von BridgeBio Oncology Therapeutics, Inc. (Ticker BBOT) f眉hrte. Im Form 4 ist eine Transaktion vom 08/11/2025 verzeichnet, bei der 30,000 Helix Class B Stammaktien im Zusammenhang mit einer Unternehmenszusammenf眉hrung und einer Domestizierung erfasst wurden, die Helix Class B eins zu eins in Helix Class A und anschlie脽end Helix Class A eins zu eins in die Stammaktien des Emittenten umwandelte.
Die Einreichung besagt, dass die meldende Person vor der Domestizierung Direktor bei Helix war und mit Wirkung zum 08/11/2025 zur眉cktrat, unmittelbar vor der Domestizierung. Nach der gemeldeten Umwandlung listet das Form 4 30,000 Aktien, die nach der Transaktion wirtschaftlich gehalten werden, und zwar direkt.
- 30,000 common shares are reported as directly beneficially owned following the conversion, clarifying the reporting persons post-transaction stake
- The filing documents a one-for-one conversion sequence from Helix Class B to Helix Class A to issuer common stock, showing clear treatment of legacy securities
- The reporting person resigned as a director of Helix effective 08/11/2025, immediately prior to the domestication
Insights
TL;DR: Conversion raised direct holdings to 30,000 BBOT common shares; director resigned immediately before domestication.
The Form 4 documents a mechanical ownership change tied to the business combination and domestication described in the explanation section. The reporting person ended up with 30,000 common shares following a one-for-one conversion sequence from Helix Class B to Helix Class A to issuer common stock. The transaction is reported with transaction code M (1) and shows direct beneficial ownership of 30,000 shares after the event. No cash purchase price is reported for the conversion in the filing.
TL;DR: Director resignation concurrent with share conversion; ownership clarified but governance change is noted.
The document confirms that the reporting person resigned as a director of Helix effective the same date as the domestication and conversion transactions. The filing therefore records both an ownership reconciliation and a corporate governance event: a resignation and the conversion of legacy Class B shares into 30,000 common shares of the successor issuer. The filing does not provide additional governance details such as replacement director information or board composition after the resignation.
John P. Schmid ha segnalato una conversione dovuta a una riorganizzazione societaria che ha comportato la titolarit脿 diretta di 30,000 azioni ordinarie di BridgeBio Oncology Therapeutics, Inc. (ticker BBOT). Il Form 4 riporta una transazione datata 08/11/2025 in cui sono state registrate 30,000 azioni ordinarie Classe B di Helix nell'ambito di una combinazione aziendale e di un trasferimento di domicilio societario che ha convertito le azioni Classe B di Helix in Classe A su base uno a uno e successivamente le azioni Classe A nelle azioni ordinarie dell'emittente, sempre uno a uno.
La comunicazione indica che la persona che ha presentato il rapporto era membro del consiglio di Helix prima della domesticazione e si 猫 dimessa con effetto 08/11/2025, immediatamente prima della domesticazione. A seguito della conversione segnalata, il Form 4 elenca 30,000 azioni possedute beneficiariamente dopo la transazione, detenute direttamente.
John P. Schmid inform贸 una conversi贸n derivada de una reorganizaci贸n corporativa que result贸 en la propiedad directa de 30,000 acciones ordinarias de BridgeBio Oncology Therapeutics, Inc. (s铆mbolo BBOT). El Form 4 muestra una transacci贸n con fecha 08/11/2025 en la que se registraron 30,000 acciones ordinarias Clase B de Helix en relaci贸n con una combinaci贸n de negocios y una domesticaci贸n que convirti贸 las Clase B de Helix en Clase A una a una y luego las Clase A en acciones ordinarias del emisor, tambi茅n una a una.
La presentaci贸n indica que la persona informante era directora de Helix antes de la domesticaci贸n y renunci贸 con efecto 08/11/2025, inmediatamente antes de la domesticaci贸n. Tras la conversi贸n reportada, el Form 4 lista 30,000 acciones de propiedad beneficiaria despu茅s de la transacci贸n, mantenidas directamente.
John P. Schmid鞚� 旮办梾 鞛幐鞙茧 鞚疙暅 鞝勴櫂鞙茧 BridgeBio Oncology Therapeutics, Inc.(韹办护 BBOT)鞚� 氤错喌欤� 30,000欤茧ゼ 歆侅为 氤挫湢頃橁矊 霅橃棃雼り碃 氤搓碃頄堨姷雼堧嫟. Form 4鞐愲姅 08/11/2025鞚检瀽 瓯半灅臧� 旮办灛霅橃柎 鞛堨溂氅�, 靷梾 瓴绊暕 氚� 氩曥澑 甑偞頇�(domestication)鞕� 甏�霠晿鞐� Helix 韥措灅鞀� B 氤错喌欤� 30,000欤缄皜 旮半霅橃棃瓿�, 鞚措摛鞚� 1雽�1搿� Helix 韥措灅鞀� A搿� 鞝勴櫂霅� 霋� 雼れ嫓 1雽�1搿� 氚滍枆須岇偓鞚� 氤错喌欤茧 鞝勴櫂霅� 瓴冹溂搿� 雮橅儉雮╇媹雼�.
靹滊鞐愲姅 氤搓碃鞚胳澊 domestication 鞚挫爠鞐� Helix鞚� 鞚挫偓鞓�鞙茧┌ domestication 歆侅爠鞐� 08/11/2025鞛愲 靷瀯頄堧嫟瓿� 鞝來榾 鞛堨姷雼堧嫟. 氤搓碃霅� 鞝勴櫂 鞚错泟 Form 4鞐愲姅 瓯半灅 頉� 靾橅槣鞝� 靻岇湢搿滌劀 30,000欤茧ゼ 歆侅为 氤挫湢頃橁碃 鞛堧姅 瓴冹溂搿� 霌膘灛霅橃柎 鞛堨姷雼堧嫟.
John P. Schmid a d茅clar茅 une conversion li茅e 脿 une r茅organisation d'entreprise ayant entra卯n茅 la propri茅t茅 directe de 30,000 actions ordinaires de BridgeBio Oncology Therapeutics, Inc. (symbole BBOT). Le Form 4 indique une op茅ration dat茅e du 08/11/2025 au cours de laquelle 30,000 actions ordinaires de classe B de Helix ont 茅t茅 enregistr茅es dans le cadre d'une fusion d'entreprise et d'une domestication qui a converti les actions Helix de classe B en classe A sur une base un pour un, puis les actions de classe A en actions ordinaires de l'茅metteur, 茅galement un pour un.
Le d茅p么t pr茅cise que la personne d茅clar茅e 茅tait administrateur chez Helix avant la domestication et a d茅missionn茅 avec effet au 08/11/2025, imm茅diatement avant la domestication. Suite 脿 la conversion signal茅e, le Form 4 indique 30,000 actions d茅tenues b茅n茅ficiairement apr猫s la transaction, d茅tenues directement.
John P. Schmid meldete eine durch eine Unternehmensumstrukturierung veranlasste Umwandlung, die zu unmittelbarem Eigentum an 30,000 Stammaktien von BridgeBio Oncology Therapeutics, Inc. (Ticker BBOT) f眉hrte. Im Form 4 ist eine Transaktion vom 08/11/2025 verzeichnet, bei der 30,000 Helix Class B Stammaktien im Zusammenhang mit einer Unternehmenszusammenf眉hrung und einer Domestizierung erfasst wurden, die Helix Class B eins zu eins in Helix Class A und anschlie脽end Helix Class A eins zu eins in die Stammaktien des Emittenten umwandelte.
Die Einreichung besagt, dass die meldende Person vor der Domestizierung Direktor bei Helix war und mit Wirkung zum 08/11/2025 zur眉cktrat, unmittelbar vor der Domestizierung. Nach der gemeldeten Umwandlung listet das Form 4 30,000 Aktien, die nach der Transaktion wirtschaftlich gehalten werden, und zwar direkt.
FAQ
What did John P. Schmid report on the Form 4 for HLXB/BBOT?
How many shares does John P. Schmid beneficially own after the reported transaction?
Why were Helix Class B shares converted according to the Form 4?
Did John P. Schmid pay cash for the converted shares?
Did the reporting person change any roles at the company?
